Foster Dykema Cabot & Co’s AstraZeneca AZN Stock Holding History

Foster Dykema Cabot & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$88K	Hold	648	–	–	0.01%	143
2023 Q2	$93K	Buy	+648	New	+$95.3K	0.01%	143

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Foster Dykema Cabot & Co's AZN Position: Q3 2023 in Review

Foster Dykema Cabot & Co held its AstraZeneca (AZN) position steady in Q3 2023 at 648 shares worth $88K. The position accounts for 0.01% of the portfolio, ranked #143.

Foster Dykema Cabot & Co first reported a position in AZN in Q2 2023 and has held it in 2 quarters since. The position peaked at $93K in Q2 2023. 1,074 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Foster Dykema Cabot & Co held 648 shares of AstraZeneca worth $88K as of Q3 2023.
Foster Dykema Cabot & Co left its AstraZeneca share count unchanged in Q3 2023.
AstraZeneca made up 0.01% of Foster Dykema Cabot & Co's portfolio in Q3 2023, its #143 holding.
Foster Dykema Cabot & Co first reported a position in AstraZeneca in Q2 2023 and has held it in 2 quarters since.
Foster Dykema Cabot & Co's AstraZeneca position peaked at $93K in Q2 2023.
1,074 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.